Zheng Wei, Connect Biopharma CEO
Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data
A suite of drugmakers is looking to topple Dupixent in the eczema market — and on Thursday, China-based Connect Biopharma uncorked some mid-stage results it says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.